MEA Respiratory Tract Infection Treatment Market Size and Forecast (2021 – 2031)

According to our new research study on “MEA Respiratory Tract Infection Treatment Market Size and Forecast to 2031 – Country Analysis – by Drugs, Disease Indication, ROA, Age Group, and Distribution Channel,” the market is expected to grow from US$ 2.09 billion in 2023 to US$ 2.97 billion by 2031; it is estimated to record a CAGR of 4.50% during 20222023-20310.

Respiratory tract infections, or RTIs, are infections of the sinuses, throat, airways, or lungs. Though most RTIs resolve on their own, occasionally, a visit to your doctor may be necessary. The MEA respiratory tract infection treatment market report emphasizes the key factors driving the market and depicts the developments of prominent players. Key factors driving the market growth include the rising cases of respiratory infections in the Middle East, and increasing awareness related to respiratory tract infections. However, the lack of research focused on respiratory therapeutics hinders market growth. Further, the advent of antiviral treatment for MERS is expected to bring new MEA respiratory tract infection treatment market trends in the coming years.

The Middle East has been experiencing a rise in cases of respiratory infections, mainly driven by factors such as air pollution, smoking prevalence, crowded living conditions, and seasonal viral outbreaks. According to the NCBI data published in 2019, acute lower respiratory tract infections are a serious health issue that impacts nearly 15% of the Saudi population annually. Epidemiological research carried out during the past three decades suggests that most of these diseases are caused by viruses. As per the Saudi German Hospitals Group UAE, ~13% of adults and 20% of children in Dubai suffer from asthma, making it a serious health concern. Variables such as lifestyle decisions, genetic predisposition, and environmental triggers can be related to such a high incidence of asthma. The increasing burden of respiratory tract infections has created a demand for effective treatment options. Pharmaceutical companies capitalize on such growing needs by developing and offering innovative therapies. Moreover, with a focus on research and development, public–private partnerships, and awareness initiatives, they can play a crucial role in addressing challenges posed by respiratory infections in the Middle East. Zoetis, Inc., Secure Diagnostics, Thermo Fisher Scientific, Inbios India, Ubio Bitechnology Systems, Gold Standerd Diagnostics, VMRD Inc., Fujifilm, Randox Laboratories Ltd, and Idexx Laboratories are among the leading companies operating in the MEA respiratory tract infection treatment market.

The report segments the MEA respiratory tract infection treatment market as follows:

In terms of drug, the antibiotics segment held the largest MEA respiratory tract infection treatment market share in 2023. The same is anticipated to register the highest CAGR during 2023–2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens.

Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023The lower respiratory tract infection segment held a larger market share in 2023 based on disease indication. It is further anticipated to register a higher CAGRhat a higher CAGR will be registered from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others.

By route of administration, the oral segment held a larger share of the MEA respiratory tract infection treatment market; the same segment is anticipated to register a higher CAGR during 2023–2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections.

In terms of age group, the adult segment held a larger share of the MEA respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023–2031. The high prevalence of respiratory tract infections among children is a key factor driving the need for effective treatment options.

In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023–2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications.

MEA Respiratory Tract Infection Treatment Market: Competitive Landscape and Key Developments

Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Orion Corporation, and Julphar are among the prominent players profiled in the MEA respiratory tract infection treatment market report. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.

 

1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Respiratory Tract Infection Treatment Market Landscape
4.1 Overview
4.2 PEST Analysis
5. MEA Respiratory Tract Infection Treatment Market – Key Market Dynamics
5.1 MEA Respiratory Tract Infection Treatment Market – Key Market Dynamics
5.2 Key Market Drivers
5.2.1 Rising Cases of Respiratory Infections in Middle East
5.2.2 Increasing Awareness Related to Respiratory Tract Infections
5.3 Key Market Restraints
5.3.1 Lack of Research Focused on Respiratory Therapeutics
5.4 Key Market Opportunities
5.4.1 Surge in Demand for OTC Products to Treat Respiratory Infections
5.5 Future Trends
5.5.1 Advent of Antiviral Treatment for MERS
5.6 Impact of Drivers and Restraints:
6. MEA Respiratory Tract Infection Treatment Market Analysis
6.1 MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023–2031
7. MEA Respiratory Tract Infection Treatment Market Analysis – by Drugs
7.1 Antibiotics
7.1.1 Overview
7.1.2 Antibiotics: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.2 NSAIDs
7.2.1 Overview
7.2.2 NSAIDs: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Cough Suppressants
7.3.1 Overview
7.3.2 Cough Suppressants: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Nasal Decongestants
7.4.1 Overview
7.4.2 Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
8. MEA Respiratory Tract Infection Treatment Market Analysis – by Disease Indication
8.1 Lower Respiratory Tract Infection
8.1.1 Overview
8.1.2 Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Upper Respiratory Tract Infection
8.2.1 Overview
8.2.2 Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
9. MEA Respiratory Tract Infection Treatment Market Analysis – by Route Of Administration
9.1 Oral
9.1.1 Overview
9.1.2 Oral: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Parenteral
9.2.1 Overview
9.2.2 Parenteral: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
10. MEA Respiratory Tract Infection Treatment Market Analysis – by Age Group
10.1 Pediatrics
10.1.1 Overview
10.1.2 Pediatrics: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Adults
10.2.1 Overview
10.2.2 Adults: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
11. MEA Respiratory Tract Infection Treatment Market Analysis – by Distribution Channel
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12. MEA Respiratory Tract Infection Treatment Market – Country Analysis
12.1 Middle East and Africa
12.1.1 MEA Respiratory Tract Infection Treatment Market Breakdown by Countries
12.1.2 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis – by Country
12.1.3 MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2030
12.1.3.1 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis – by Country
12.1.3.2 Saudi Arabia
12.1.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12.1.3.3.1 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
12.1.3.3.2 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
12.1.3.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
12.1.3.3.4 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
12.1.3.3.5 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
12.1.3.4 South Africa
12.1.3.5 South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12.1.3.5.1 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
12.1.3.5.2 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
12.1.3.5.3 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
12.1.3.5.4 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
12.1.3.5.5 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
12.1.3.6 UAE
12.1.3.7 UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12.1.3.7.1 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
12.1.3.7.2 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
12.1.3.7.3 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
12.1.3.7.4 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
12.1.3.7.5 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
12.1.3.8 Rest of MEA
12.1.3.9 REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12.1.3.9.1 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
12.1.3.9.2 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
12.1.3.9.3 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
12.1.3.9.4 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
12.1.3.9.5 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
13. Company Profiles
13.1 Abbott Laboratories
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Teva Pharmaceutical Industries Ltd
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Sanofi SA
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Boehringer Ingelheim International GmbH
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 AstraZeneca Plc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Alembic Pharmaceuticals Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 GSK Plc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Novartis AG
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. Hoffmann-La Roche Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Gulf Pharmaceutical Industries Co
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Research Team
14.2 Glossary of Terms

Table 1. MEA Respiratory Tract Infection Treatment Market Segmentation
Table 2. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs
Table 3. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication
Table 4. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration
Table 5. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group
Table 6. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 7. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Country
Table 8. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs
Table 9. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication
Table 10. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration
Table 11. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group
Table 12. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 13. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs
Table 14. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication
Table 15. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration
Table 16. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group
Table 17. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 18. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs
Table 19. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication
Table 20. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration
Table 21. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group
Table 22. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 23. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs
Table 24. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication
Table 25. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration
Table 26. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group
Table 27. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 28. Glossary of Terms, MEA Respiratory Tract Infection Treatment Market

Figure 1. MEA Respiratory Tract Infection Treatment Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023–2031
Figure 5. MEA Respiratory Tract Infection Treatment Market Share (%) – by Drugs, 2023 and 2031
Figure 6. Antibiotics: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 7. NSAIDs: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 8. Cough Suppressants: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 9. Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 10. MEA Respiratory Tract Infection Treatment Market Share (%) – by Disease Indication, 2023 and 2031
Figure 11. Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 12. Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 13. MEA Respiratory Tract Infection Treatment Market Share (%) – by Route Of Administration, 2023 and 2031
Figure 14. Oral: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 15. Parenteral: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 16. MEA Respiratory Tract Infection Treatment Market Share (%) – by Age Group, 2023 and 2031
Figure 17. Pediatrics: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 18. Adults: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 19. MEA Respiratory Tract Infection Treatment Market Share (%) – by Distribution Channel, 2023 and 2031
Figure 20. Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 21. Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 22. Online Pharmacies: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)
Figure 23. MEA Respiratory Tract Infection Treatment Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 24. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2030(US$ Million)
Figure 25. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)